The GLP-1 receptor agonist class has revolutionized obesity medicine over the past five years, but "GLP-1" as a single category obscures three quite different products. Semaglutide (Wegovy for obesity, Ozempic for T2D) is a single GLP-1 receptor…
MEMBERS ONLY
Continue Reading
This article is available to Vanguard members. Join to access all physician-curated content.